Abstract

BackgroundAnti-TNF alpha (TNFi) drug survival is one of the relevant outcome measure in rheumatological diseases.ObjectivesObjective of this study was to compare TNFi drug survival in ankylosing spondylitis (AS) and axial...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0347 Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis HAD Similar TNFI Drug Survival: HÜR-BİO REAL Life Results
...
Annals of the Rheumatic Diseases | VOL. 73
, et. al. ...
01 Jun 2014
SAT0412 Patients with Psoriatic Arthritis HAD Better TNFI Survival than Ankylosing Spondylitis: HÜR-BİO REAL Life Results
U Kalyoncu ... L Kilic
Annals of the Rheumatic Diseases | VOL. 73
U Kalyoncu, et. al.U Kalyoncu ... L Kilic
01 Jun 2014
SAT0367 Frequency of Radiological Hip Involvement and Total Hip Replacement in A Large Single Center Spondyloarthritis Cohort with Biological Treatments: HÜR-BİO REAL Life Results
U Kalyoncu ... I Ertenli
Annals of the Rheumatic Diseases | VOL. 73
U Kalyoncu, et. al.U Kalyoncu ... I Ertenli
01 Jun 2014
SAT0370 Retention Rate of TNF Blockers is Greater in CASE of Advanced Spinal Ankylosis in Axial Spondyloarthritis: Data from the HÜR-BİO Registry
U Kalyoncu ... O Karadag
Annals of the Rheumatic Diseases | VOL. 73
U Kalyoncu, et. al.U Kalyoncu ... O Karadag
01 Jun 2014
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.